Please assess the completion status of the following clinical trial:

Trial Title: Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent is obtained in the English language;~* They are a 18 to 95 years old;~* They meet United Kingdom Brain Bank Criteria for probable idiopathic Parkinson disease;~* They meet Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive disorder (MDD) as diagnosed by the M.I.N.I. at screening;~* They are judged by the investigator to have the capacity to understand the nature of the study;~* They are willing to comply with all the requirements of the study;~* They are considered by the investigator to be likely to adhere to the protocol.~Exclusion Criteria:~* They have been treated with onabotulinumtoxinA injected into the facial muscles for any reason in the 3 months prior to screening;~* They have Bipolar Disorder, Post-Traumatic Stress Disorder, a Psychotic Disorder or any other non-unipolar depressive disorder as a principal diagnosis in the 6 months prior to screening;~* They endorse active suicidal ideation at enrollment or during any study visit, or have attempted suicide in the six months prior to screening;~* They have a history of substance abuse or dependence in the 2 months prior to screening;~* They test positive for illicit drugs on urine screen, and this has not been adequately explained to the satisfaction of the investigator~* They are considered to be at significant risk of committing homicide;~* They have an unstable medical condition;~* Women of childbearing potential who are pregnant or are considering becoming pregnant during the length of the study;~* There has been a change in their PD medication or psychotherapy treatment regimen in the 30 days preceding screening;~* They are regarded, for any reason, by the principal investigator as being an unsuitable candidate for the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
- Control (Type: PLACEBO_COMPARATOR): One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.

Based on this trial design, predict the completion outcome and termination type (if applicable).